Phytohealth Corp (4108) Fair Value & Analysis
Healthcare · TW · Market cap 2.3B TWD
Risks
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 11 days ago
Share price −6.0% over the past month.
Below-average quality, and trading another 180% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (4.93 TWD). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (2.60 TWD to 4.93 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 10.75 TWD – 29.05 TWD · fair‑value band 2.60 TWD – 4.93 TWD · the 11.05 TWD price screens above the 3.95 TWD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Phytohealth Corp (4108) currently trades at 11.05 TWD, while our model-based Fair Value estimate is 3.95 TWD, implying the stock looks roughly 64.3% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Phytohealth Corp generated revenue of 139M TWD at a net margin of -42.7%. Revenue grew 13.0% year over year. It earns a return on equity of -4.8%. The balance sheet holds a net cash position of 71.1M TWD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 2.60 TWD (bear case) to 4.93 TWD (bull case); at 11.05 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -35% fair-value upside, at -64%, 4108 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 4108 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
PhytoHealth Corporation researches, develops, manufactures, and sells medicines, cosmetics, Class B medicines, complementary foods, and other related products in Taiwan. It operates in three segments: Medicines and Health Food, Medical Diagnosis, and Precision Medical Equipment and Instruments.
Full company description
PhytoHealth Corporation researches, develops, manufactures, and sells medicines, cosmetics, Class B medicines, complementary foods, and other related products in Taiwan. It operates in three segments: Medicines and Health Food, Medical Diagnosis, and Precision Medical Equipment and Instruments. The Medicines and Health Food segment manufactures and sells Chinese medicine materials and new drugs. The Medical Diagnosis segment develops and sells smart medical imaging diagnostic products. The Precision Medical Equipment and Instruments segment engages in the research and development, manufacturing, and sale of ultrasound probes and analysis systems. Its products under development include PHN031, which has completed Phase II clinical trials for the treatment of osteoporosis, and PHN033, which has completed Phase II clinical trials for the treatment of diabetic nephropathy. The company is also developing PHN016, which is in Phase II clinical trials for the treatment of cancer, and PHN017, which is in Phase I trials for the treatment of severe infection-induced cytokine storm. In addition, it offers PG2 Lyophilized Injection for the treatment of cancer-related fatigue and capsules for acute moderate to severe pain. PhytoHealth Corporation was incorporated in 1998 and is based in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Phytohealth Corp reported revenue of 135M TWD in FY2025 versus 169M TWD in FY2021, a compound −5.5%/yr. Reported net income was −58.2M TWD in FY2025.
4108 screens 64% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 635 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.00 | €106.48 | -24% |
| Takeda Pharmaceutical Company TAK | $17.41 | $11.29 | -35% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | -69% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Haleon plc HLN | $9.80 | $7.62 | -22% |
| Teva Pharmaceutical Industries Limited TEVA | $36.74 | $15.37 | -58% |
| Sandoz Group SDZ | CHF 72.64 | CHF 48.68 | -33% |
| Zoetis Inc ZTS | $73.54 | $104.88 | +43% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | -52% |
Compare Phytohealth Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Phytohealth Corp (4108) overvalued or undervalued?
What is the fair value of 4108?
What is the quality score of 4108?
What is the revenue of Phytohealth Corp (4108)?
What is the net profit margin of 4108?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Phytohealth Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.